Skip to content

Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Cervical

Multicenter Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Cervical - a Prospective Study on Total Indications

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05296889
Acronym
CERISE
Enrollment
200
Registered
2022-03-25
Start date
2021-07-21
Completion date
2028-09-01
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative Disc Disease, Degenerative Myelopathy, Spinal Instability, Spinal Tumor, Spine Fracture

Keywords

Cervical Spine

Brief summary

Multicenter Post market clinical follow-up Study on the Safety and Performance of Ennovate® Cervical - Prospective, pure data collection of all Ennovate Cervical patients in Total Indications

Detailed description

This clinical study is one of the Post market clinical follow-up measures that enables the manufacturer to monitor the clinical safety and performance of the Ennovate® Cervical system. The study enables a quick, but detailed implant documentation, which is of great interest for the current and future users of the internal fixation system targeted in this study. It includes the relevant outcomes to evaluate safety and efficacy of the implant system for various indications in trauma and degenerative disorders.

Interventions

The Ennovate® Cervical Spinal System is a posterior stabilization for the cervical and upper-thoracic spine. The implants are used for the posterior monosegmental and multisegmental stabilization of the occipitocervical junction and of the cervical and upper thoracic spine.

Sponsors

Aesculap AG
Lead SponsorINDUSTRY
Raylytic GmbH
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient is minimum 18 years old * Informed Consent in the documentation of clinical and radiological results * Patient has indication according to Instructions for Use (IFU) * Patient is not pregnant

Exclusion criteria

* Patient's clear unability or unwillingness to participate in follow-up examinations

Design outcomes

Primary

MeasureTime frameDescription
Change of Painpreoperatively, at 3 months postoperatively and at 12 months postoperativelyPain will be assessed by the patient using the Visual Analogue Scale (VAS) which states "0" at one end representing "no pain" and "100" at the opposite end representing "maximal/worst pain".

Secondary

MeasureTime frameDescription
Change of Quality of lifepreoperatively, at 3 months postoperatively and at 12 months postoperativelyIn order to analyze the quality of life of the patients, the 5-dimension 5-level score of EuroQol Group (EQ-5D-5L) is used. The score is self-completed by the patient. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Change of Neurological statuspreoperatively, at 3 months postoperatively and at 12 months postoperativelyThe Japanese Orthopaedic Association (JOA) myelopathy score is a disease-specific and physician oriented system that mainly assesses the neurological status of the patient and enables surgeons to compare the changes in the neurological status of the patient before and after certain treatments. However, the JOA score does not include patients' satisfaction, disability, handicaps, or general health (physical and mental health), which can be affected by cervical myelopathy.
Change of Disabilitypreoperatively, at 3 months postoperatively and at 12 months postoperativelyThe Neck Disability Index (NDI) is designed to measure neck-specific disability. The questionnaire has 10 items to measure patient-reported disability secondary to neck pain and activities of daily living including personal care, lifting, reading, headaches, concentration, work status, driving, sleeping and recreation and patients rate their status from 0 (best) to 5 (worst imaginable). Individual item responses are summed to a total score, where 0 points indicate no activity limitations and 50 points indicate complete activity limitation.
Bone fusionat final follow-up 12 months postoperativelyAfter cervical stabilization fusion of the treated segment is aspired in most cases. The fusion status can be determined from radiographs (static or dynamic). Bony fusion can be characterized quantitatively by the fusion rate.
Cumulative number of side effectsthroughout the follow-up up to 12 months postoperativelyOccurrence of complications potentially associated with the implanted devices can never be fully excluded during spinal surgery. In order to monitor potential complication and to identify so far unknown complications Adverse Events and Serious Adverse Events deemed related to the investigational device are recorded.

Countries

Germany

Contacts

CONTACTSarah Mattes
sarah.mattes@aesculap.de+497461950
CONTACTStefan Maenz, Dr.
stefan.maenz@aesculap.de+497461950

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 4, 2026